novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"), seasonal influenza, pandemic influenza, and ebola virus ("ebov"). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
Company profile
Ticker
NVAX
Exchange
Website
CEO
Stanley Erck
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
14 Firstfield Holdings, LLC • Novavax NL B.V. • Novavax DE GmbH • Novavax AB • Novavax UK Limited • Novavax CH GmbH • Novavax FR SAS ...
IRS number
222816046
NVAX stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
26 Mar 24
8-K
Novavax Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Entry into a Material Definitive Agreement
22 Feb 24
8-K
Cost Associated with Exit or Disposal Activities
31 Jan 24
8-K
Results of Operations and Financial Condition
8 Jan 24
8-K
Other Events
5 Dec 23
8-K
Novavax Makes Changes to Executive Leadership Team to Enhance Focus on Delivery of Strategic Priorities
17 Nov 23
8-K
Novavax Reports Third Quarter 2023 Financial Results and Operational Highlights
9 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
Transcripts
NVAX
Earnings call transcript
2023 Q4
28 Feb 24
NVAX
Earnings call transcript
2023 Q3
9 Nov 23
NVAX
Earnings call transcript
2023 Q2
8 Aug 23
NVAX
Earnings call transcript
2023 Q1
9 May 23
NVAX
Earnings call transcript
2022 Q4
28 Feb 23
NVAX
Earnings call transcript
2022 Q3
8 Nov 22
NVAX
Earnings call transcript
2022 Q2
9 Aug 22
NVAX
Earnings call transcript
2022 Q1
10 May 22
NVAX
Earnings call transcript
2021 Q4
1 Mar 22
NVAX
Earnings call transcript
2021 Q3
5 Nov 21
Latest ownership filings
SC 13D/A
SHAH CAPITAL MANAGEMENT
15 Apr 24
SC 13D
SHAH CAPITAL MANAGEMENT
15 Apr 24
4
John Trizzino
26 Mar 24
4
Elaine O'Hara
26 Mar 24
4
James Patrick Kelly
26 Mar 24
4
Filip Dubovsky
26 Mar 24
4
Mark J Casey
26 Mar 24
4
John C Jacobs
26 Mar 24
4
James Patrick Kelly
12 Mar 24
4
Filip Dubovsky
12 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 666.36 mm | 666.36 mm | 666.36 mm | 666.36 mm | 666.36 mm | 666.36 mm |
Cash burn (monthly) | (no burn) | 52.22 mm | 43.82 mm | 52.52 mm | 13.22 mm | 54.58 mm |
Cash used (since last report) | n/a | 355.77 mm | 298.56 mm | 357.81 mm | 90.05 mm | 371.86 mm |
Cash remaining | n/a | 310.59 mm | 367.80 mm | 308.55 mm | 576.31 mm | 294.50 mm |
Runway (months of cash) | n/a | 5.9 | 8.4 | 5.9 | 43.6 | 5.4 |
Institutional ownership, Q3 2023
48.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 226 |
Opened positions | 46 |
Closed positions | 34 |
Increased positions | 64 |
Reduced positions | 51 |
13F shares | Current |
---|---|
Total value | 399.72 bn |
Total shares | 68.31 mm |
Total puts | 10.95 mm |
Total calls | 8.08 mm |
Total put/call ratio | 1.4 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 11.55 mm | $83.63 bn |
STT State Street | 10.17 mm | $73.66 bn |
BLK Blackrock | 7.07 mm | $51.16 bn |
SK Bioscience | 6.50 mm | $47.00 mm |
Shah Capital Management | 6.33 mm | $45.83 mm |
Millennium Management | 2.56 mm | $18.51 bn |
MS Morgan Stanley | 2.28 mm | $16.47 bn |
Geode Capital Management | 1.86 mm | $13.48 bn |
C Citigroup | 1.56 mm | $11.33 bn |
Balyasny Asset Management | 1.38 mm | $9.99 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
10 Mar 24 | James Patrick Kelly | Common Stock | Payment of exercise | Dispose F | No | No | 5.45 | 2,226 | 12.13 k | 13,285 |
10 Mar 24 | James Patrick Kelly | Common Stock | Option exercise | Acquire M | No | No | 0 | 4,608 | 0.00 | 15,511 |
10 Mar 24 | James Patrick Kelly | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 4,608 | 0.00 | 4,608 |
10 Mar 24 | Filip Dubovsky | Common Stock | Payment of exercise | Dispose F | No | No | 5.45 | 2,597 | 14.15 k | 66,613 |
10 Mar 24 | Filip Dubovsky | Common Stock | Option exercise | Acquire M | No | No | 0 | 5,376 | 0.00 | 69,210 |
10 Mar 24 | Filip Dubovsky | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 5,376 | 0.00 | 5,376 |
10 Mar 24 | Trizzino John | Common Stock | Payment of exercise | Dispose F | No | No | 5.45 | 2,226 | 12.13 k | 27,972 |
10 Mar 24 | Trizzino John | Common Stock | Option exercise | Acquire M | No | No | 0 | 4,608 | 0.00 | 30,198 |
10 Mar 24 | Trizzino John | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 4,608 | 0.00 | 4,608 |
7 Mar 24 | Filip Dubovsky | Common Stock | Payment of exercise | Dispose F | No | No | 5.61 | 9,392 | 52.69 k | 63,834 |
News
Novavax To Supply Updated COVID-19 Vaccine To Private Healthcare Providers In The United Kingdom
18 Apr 24
What's Going On With Novavax Stock Today?
15 Apr 24
Shah Capital Nominates Two Independent Director Candidates For Novavax
15 Apr 24
10 Health Care Stocks With Whale Alerts In Today's Session
9 Apr 24
Novavax Presents Data On Updated COVID-19 Vaccine And Progress To Date On Its COVID-19-Influenza Combination Vaccine Candidate At World Vaccine Congress 2024
1 Apr 24
Press releases
Shah Capital nominates two highly qualified independent director candidates for Novavax
15 Apr 24
Novavax to Participate in TD Cowen's 44th Annual Health Care Conference
29 Feb 24
Exploring Stocks with High Short Interest: INBS, BLNK, BYND, NVAX, PLUG
27 Feb 24
Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase Agreement
22 Feb 24
Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights on February 28, 2024
20 Feb 24